Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2009
06/23/2009CA2389219C Dry powder compositions having improved dispersivity
06/23/2009CA2373466C Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (eaoh)
06/23/2009CA2367387C Composition comprising isoquercetin and ascorbic acid in a sustained release form
06/23/2009CA2319686C Use of 2-amino-6-trifluoromehthoxybenzothiazole for preventing or treating cerebellum dysfunction
06/23/2009CA2300148C Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
06/21/2009CA2776673A1 Composition comprising an extract of red mold rice for treatment of alzheimer's disease
06/19/2009CA2655335A1 Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
06/18/2009WO2009076664A1 Method and composition for treating a serotonin receptor-mediated condition
06/18/2009WO2009076593A1 Modulators of cystic fibrosis transmembrane conductance regulator
06/18/2009WO2009076352A1 Gamma secretase modulators
06/18/2009WO2009076337A1 Gamma secretase modulators
06/18/2009WO2009076236A2 Micronized opioid compositions, formulations and dosage forms and methods of making same
06/18/2009WO2009075874A1 Gamma secretase modulators
06/18/2009WO2009075857A2 Glycine transporter-1 inhibitors
06/18/2009WO2009075691A1 Cb-1 modulating compounds and their use
06/18/2009WO2009075677A1 O-desmethyl-venlafaxine for treating major depressive disorder
06/18/2009WO2009075557A1 Fluorobenzenamides having anti-convulsive activity
06/18/2009WO2009075349A1 Element retained in blood showing degradability selectively in tumor tissue
06/18/2009WO2009075277A1 4-aminopyrimidine derivative and medicinal composition containing the compound
06/18/2009WO2009075084A1 Agent and method for diagnosis on the occurrence of alzheimer's disease or the tendency to develop alzheimer's disease
06/18/2009WO2009074607A1 Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
06/18/2009WO2009074519A1 Combinations of pyrazolyl or isoxazolyl p2x7 modulators with further therapeutic agents
06/18/2009WO2009074518A1 Combinations of prolinamide p2x7 modulators with further therapeutic agents
06/18/2009WO2009074478A1 Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
06/18/2009WO2009074333A1 Synthesis of paliperidone
06/18/2009WO2009054923A3 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
06/18/2009WO2009053536A3 Splice variants of gdnf and uses thereof
06/18/2009WO2009046864A3 Use of the human pancreatic polypeptide as a therapeutic agent
06/18/2009WO2009046847A3 Use of peptide ll-37 as a therapeutic agent
06/18/2009WO2009046846A3 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent
06/18/2009WO2009044019A3 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
06/18/2009WO2009044018A3 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics
06/18/2009WO2009043476A3 Neuromedin s as a therapeutic agent
06/18/2009WO2009043448A3 Neuromedin u-25 and neuromedin s as therapeutic agents
06/18/2009WO2009043440A3 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
06/18/2009WO2009038385A3 Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
06/18/2009WO2009037394A3 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof
06/18/2009WO2008056266A8 Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives
06/18/2009WO2007109749A8 Methods for preventing and treating amyloidogenic diseases
06/18/2009US20090156803 Condensed furan compounds
06/18/2009US20090156679 Levodopa prodrug mesylate, compositions thereof, and uses thereof
06/18/2009US20090156678 Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
06/18/2009US20090156677 Gabapentin-containing Solid Compositions and Process for Preparing the Same
06/18/2009US20090156640 Nociceptin analogs
06/18/2009US20090156639 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
06/18/2009US20090156631 Controlled Release Compositions Containing Zolpidem
06/18/2009US20090156626 Treating conditions associated with the nociceptin/ORL1 receptor system, e.g. pain, drug withdrawal, anxiety, muscle relaxants, anxiolytic agents; e.g. 1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-3,4-dihydro-1H-2,9-diazafluorene
06/18/2009US20090156619 Heterocycle Substituted Amide and Sulfur Amide Derivatives as Histone Deacetylase (HDAC) Inhibitors
06/18/2009US20090156618 1-(1- (2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino) - 1H-Pyrazolo [4,3-D] Pyrimidin-5-YL) Piperidine-4-Carboxylic acid and salts thereof
06/18/2009US20090156607 2-oxo-1-pyrrolidine derivatives
06/18/2009US20090156599 Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
06/18/2009US20090156597 Novel Compounds
06/18/2009US20090156593 Spirocyclic Azaindole Derivatives
06/18/2009US20090156591 Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors
06/18/2009US20090156590 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions
06/18/2009US20090156585 Organic compounds
06/18/2009US20090156565 Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
06/18/2009US20090156561 Use of Cholinesterase Inhibitors In Smoking Cessation
06/18/2009US20090156557 Kinase inhibitors
06/18/2009US20090156527 Antiviral oligonucleotides targeting viral families
06/18/2009US20090156525 Low-Density Lipoprotein Receptor-Related Protein 2 Clears Amyloid-Beta Peptide A cross the Blood-Brain Barrier via Apolipoprotein J
06/18/2009US20090156524 Novel siRNAS and methods of use thereof
06/18/2009US20090156513 freeze-dried fruit pulp powder; antioxidants comprises a high concentration of anthocyanin; treating disease or injury and damage induced by pathological free radicals; has a cyclooxygenase inhibition value greater than Aspirin; anticarcinogenic, antiinflammatory, antiarthritic agents; aging resistance
06/18/2009US20090156507 Cell permeable conjugates of peptides for inhibition of protein kinases
06/18/2009US20090156501 Identification of ligands by selective amplification of cells transfected with receptors
06/18/2009US20090156500 Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
06/18/2009US20090156498 Fusion proteins for delivery of gdnf to the cns
06/18/2009US20090156493 Urocortin-iii and uses thereof
06/18/2009US20090155906 Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line
06/18/2009US20090155398 Jucara and acai fruit-based dietary supplements
06/18/2009US20090155392 Methods and Systems for Sublingual Guarana Administration
06/18/2009US20090155389 Selective serotonin receptor inverse agonists as therapeutics for disease
06/18/2009US20090155374 Bioactive agent, a low molecular weight chitosan, and a negatively charged third component; the chitosan dominates on the nanoparticle surface; enhanced permeability for paracellular drug delivery; chewable composition
06/18/2009US20090155331 Injectable nanoparticulate olanzapine formulations
06/18/2009US20090155281 Methods of using antibodies that bind both bcma and taci
06/18/2009US20090155263 Compositions and methods for the treatment of immune related diseases
06/18/2009US20090155256 Immunotherapy Regimes Dependent On APOE Status
06/18/2009US20090155246 Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof
06/18/2009US20090155223 Cell-based compositions and methods for treating conditions of the nervous system
06/18/2009US20090155205 HUMAN ANTIBODIES THAT BIND HUMAN TNFa
06/18/2009US20090155178 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
06/18/2009DE202009003780U1 Kräuterzusammensetzung Herbal composition
06/18/2009DE202009003549U1 Variabel und präzise dosierbare feste Arzneiform enthaltend ein Antiepileptikum Variable and precisely metered solid dosage form comprising an antiepileptic drug
06/18/2009CA2845454A1 Organic compounds useful as inhibitors of phosphodiesterase 1
06/18/2009CA2709301A1 Modulators of cystic fibrosis transmembrane conductance regulator
06/18/2009CA2709104A1 Method and composition for treating a serotonin receptor-mediated condition
06/18/2009CA2708832A1 O-desmethyl-venlafaxine for treating major depressive disorder
06/18/2009CA2708780A1 Small molecules for neuronal differentiation of embryonic stem cells
06/18/2009CA2708300A1 Gamma secretase modulators
06/18/2009CA2708151A1 Gamma secretase modulators
06/18/2009CA2707969A1 Micronized opioid compositions, formulations and dosage forms and methods of making same
06/18/2009CA2707681A1 Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system
06/18/2009CA2707492A1 Gamma secretase modulators
06/18/2009CA2707305A1 Glycine transporter-1 inhibitors
06/18/2009CA2706789A1 Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
06/17/2009EP2071036A2 Methods for identifying RNA-binding compounds
06/17/2009EP2070939A1 Modulators of pharmacological agents
06/17/2009EP2070933A1 Tricyclic triazolic compounds
06/17/2009EP2070930A1 Polycycloalkylpurines as adenosine receptor antagonists
06/17/2009EP2070927A1 Fused heterocyclic derivative
1 ... 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 ... 1833